Literature DB >> 31262664

Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation.

Nicholas Ankenbruck1, Rohan Kumbhare1, Yuta Naro1, Meryl Thomas1, Laura Gardner1, Cole Emanuelson1, Alexander Deiters2.   

Abstract

MicroRNAs (miRNAs) are short, non-coding RNA molecules estimated to regulate expression of a large number of protein-coding genes and are implicated in a variety of biological processes such as development, differentiation, proliferation, and cell survival. Dysregulation of miRNAs has been attributed to the onset and progression of various human diseases, including cancer. MicroRNA-21 (miR-21), one of the most established oncogenic miRNAs, is found to be upregulated in a wide range of cancers making it an attractive therapeutic target. Employment of a luciferase-based live-cell reporter assay in a high-throughput screen of >300,000 small molecules led to the discovery of a new class of ether-amide miR-21 inhibitors. Following a structure-activity relationship study, an optimized lead molecule was found to inhibit miR-21 transcription. Furthermore, the inhibitor demonstrated cytotoxicity in a cervical cancer cell line via induction of apoptosis and was capable of reducing microtumor formation in a long-term clonogenic assay. Altogether, this work reports the discovery of a new small molecule inhibitor of miR-21 and demonstrates its potential as an alternative approach in cancer therapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 31262664     DOI: 10.1016/j.bmc.2019.05.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Optical control of protein phosphatase function.

Authors:  Taylor M Courtney; Alexander Deiters
Journal:  Nat Commun       Date:  2019-09-26       Impact factor: 14.919

Review 2.  Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy.

Authors:  Rongyan Zhao; Jiahui Fu; Lingjuan Zhu; Yi Chen; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-02-05       Impact factor: 17.388

Review 3.  Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.

Authors:  Anuradha Pandit; Yasmin Begum; Priyanka Saha; Amit Kumar Srivastava; Snehasikta Swarnakar
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

Review 4.  Noncoding RNAs Emerging as Drugs or Drug Targets: Their Chemical Modification, Bio-Conjugation and Intracellular Regulation.

Authors:  Jin Wang; Tian Tian; Xin Li; Yan Zhang
Journal:  Molecules       Date:  2022-10-09       Impact factor: 4.927

5.  Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.

Authors:  Nadeen M El-Ghobashy; Selwan M El-Sayed; Ihsan A Shehata; Mahmoud B El-Ashmawy
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

Review 6.  Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma.

Authors:  Lisa Linck-Paulus; Claus Hellerbrand; Anja K Bosserhoff; Peter Dietrich
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.